Author: Ailyn Fun

New York, NY – Altaris, LLC (collectively with its managed funds, “Altaris”) announced today that it has entered into a definitive agreement to acquire Minaris Regenerative Medicine (Minaris Regenerative Medicine, LLC in the United States, Minaris Regenerative Medicine Co., Ltd. in Japan, Minaris Regenerative Medicine GmbH in Germany, and along with its subsidiaries, “Minaris”) from Resonac Corporation, a subsidiary of Resonac Holdings Corporation (TYO: 4004) (“Resonac”). The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions.

Minaris is a cell therapy contract development and manufacturing organization (“CDMO”) that provides autologous and allogeneic manufacturing services for pharmaceutical and biotech customers globally. Founded in 1999 as Progenitor Cell Therapy, Minaris has been a pioneer in the field, including through its role in manufacturing pivotal study batches for Dendreon’s Provenge®, the first cell therapy approved for cancer treatment. Today, Minaris operates six facilities across the United States, Germany, and Japan and has more than 500 employees. Through its strategic footprint and manufacturing expertise, Minaris enables leading cell therapy companies to deliver life changing products to patients globally.

Advisors
J.P. Morgan served as financial advisor and Kirkland & Ellis LLP acted as legal counsel for Altaris. BofA Securities served as financial advisor and TMI Associates acted as legal advisor to Resonac.

About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com.

New York, NY – Altaris, LLC (collectively with its affiliates, “Altaris”) announced today that it has entered into a definitive agreement to acquire Sharecare, Inc. (NASDAQ: SHCR) (“Sharecare”) in a take-private transaction for $1.43 per share in cash (the “Transaction”), implying a total equity value of approximately $540 million. Upon consummation of the Transaction, Sharecare will become a privately held company and its common stock will no longer be traded on the NASDAQ.

The Transaction is expected to close during the second half of 2024, subject to certain customary closing conditions, including receipt of approval by Sharecare stockholders and the receipt of required regulatory approvals. Jeff Arnold, the founder of Sharecare, will roll over substantially all of his equity interests in Sharecare as part of the Transaction. Following the closing of the Transaction, Arnold and Brent Layton will continue as Executive Chairman and Chief Executive Officer of Sharecare, respectively.

Sharecare is a digital health company that provides technology and services to stakeholders across the healthcare ecosystem through its three business channels: Enterprise, Provider and Life Sciences. Sharecare’s integrated, data-driven platform engages individuals and helps them manage their care journey with solutions such as benefits navigation, coaching, health information management, and personalized content, enabling consumers, providers, employers, health plans, and government organizations to improve quality of care and drive better outcomes. Sharecare’s platform offerings currently cover 12.4 million lives and over 8,000 hospitals and physician practices.

Advisors

Houlihan Lokey Capital, Inc. and MTS Health Partners, L.P. are acting as financial advisors to the special committee of Sharecare, and Wachtell, Lipton, Rosen & Katz LLP is acting as legal advisor to the special committee of Sharecare. Kirkland & Ellis LLP is acting as legal advisor to Altaris.

About Altaris

Altaris is an investment firm exclusively focused on the healthcare industry. Altaris seeks to build market-leading companies that deliver innovation and efficiency to the healthcare system, with the ultimate goal of improving access and outcomes for patients. Altaris is headquartered in New York City and manages ~$10 billion of equity capital. For more information, please visit www.altariscap.com.

Important Notice Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “outlook,” “target,” “reflect,” “on track,” “foresees,” “future,” “may,” “deliver,” “will,” “shall,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms, other comparable terminology (although not all forward-looking statements contain these words), or by discussions of strategy, plans, or intentions. These statements involve risks, uncertainties and other factors that are, in many instances, beyond Sharecare’s and Altaris’ control and may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These statements are based on a combination of facts and factors currently known by Sharecare and Altaris and projections of the future, about which we cannot be certain.

Forward-looking statements in this communication include, but are not limited to, statements regarding the proposed transaction, including the benefits of the proposed transaction, the structure of the proposed transaction, the anticipated timing of consummation of the proposed transaction, and plans following the consummation of the proposed transaction. We cannot assure you that the forward-looking statements in this communication will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results. Risks and uncertainties include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner, or at all; (ii) the failure to satisfy the conditions to the consummation of the proposed transaction, including, without limitation, the receipt of stockholder and regulatory approvals; (iii) unanticipated difficulties or expenditures relating to the proposed transaction; (iv) the effect of the announcement or pendency of the proposed transaction on Sharecare’s plans, business relationships, operating results and operations; (v) potential difficulties retaining Sharecare employees as a result of the announcement and pendency of the proposed transaction; (vi) the response of Sharecare’s customers, channel partners and suppliers to the announcement of the proposed transaction; (vii) risks related to diverting Sharecare’s management’s attention from its ongoing business operations; and (viii) legal proceedings, including those that may be instituted against Sharecare, its board of directors, its executive officers or others following the announcement of the proposed transaction. Descriptions of some of the other factors that could cause actual results to differ materially from these forward-looking statements are discussed in more detail in Sharecare’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the Risk Factors section of Sharecare’s Annual Report on Form 10-K for the year ended December 31, 2023. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by any person that Sharecare and Altaris will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this communication speak only as of the date of this communication. Sharecare and Altaris anticipate that subsequent events and developments will cause views to change. However, while Sharecare and Altaris may elect to update these forward-looking statements at some point in the future, Sharecare and Altaris have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of Sharecare and Altaris s of any date subsequent to the date of this communication.

Additional Information and Where to Find It

This communication relates to the proposed transaction involving Sharecare, Inc. (“Sharecare”). In connection with the proposed transaction, Sharecare will file relevant materials with the SEC, including Sharecare’s proxy statement on Schedule 14A (the “Proxy Statement”). This communication is not a substitute for the Proxy Statement or for any other document that Sharecare may file with the SEC and send to its stockholders in connection with the proposed transaction. The proposed transaction will be submitted to Sharecare’s stockholders for their consideration. BEFORE MAKING ANY VOTING DECISION, SHARECARE’S STOCKHOLDERS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Sharecare’s stockholders will be able to obtain a free copy of the Proxy Statement, as well as other filings containing information about Sharecare, without charge, at the SEC’s website (www.sec.gov). Copies of the Proxy Statement and the filings with the SEC that will be incorporated by reference therein will also be available, without charge, by directing a request to Sharecare, Inc., 255 East Paces Ferry Road NE, Suite 700, Atlanta, Georgia 30305, Attention: Investor Relations, investors@sharecare.com, or from Sharecare’s website www.sharecare.com.

Telford, PA – Solesis announced today the appointment of John Witkowski as the company’s Chief Executive Officer.

Mr. Witkowski brings nearly 30 years of experience across the medical device and biopharmaceutical industries. Most recently he served as President of DSM Biomedical, the global biomaterials division of dsm-firmenich, where he led a significant period of transformational growth for DSM Biomedical.

Mr. Witkowski is well positioned to lead Solesis in its next phase of growth and brings a strong track record of building high-quality businesses, both organically and through M&A. The Solesis board welcomes Mr. Witkowski and is excited about working with him to grow Solesis and its subsidiaries, Secant Group, Polyzen, and Charter Medical.

About Solesis:

Solesis is a leader specializing in biomaterials for the life sciences industry. Operating through its subsidiaries Secant Group, Polyzen, and Charter Medical, Solesis develops and manufactures critical components and technologies for the medical device and biopharmaceutical industries. Headquartered in Telford, Pennsylvania, Solesis employs more than 450 people across five production facilities located in Pennsylvania and North Carolina. For more information, please visit www.solesis.com.

Partnership with Leading Venture Platform is Another Step Forward in Clearwater’s Initiative to Help Secure the Next Generation of Healthcare Technology Innovators

NASHVILLE, TN – Clearwater, the largest pure-play provider of cybersecurity and compliance solutions for the healthcare industry, and 25m Health, part of the Venture Platform 25madison that incubates and invests in breakout healthcare technology startups, announced today a partnership focused on developing a repeatable and scalable cybersecurity and compliance program that can deployed across the organization and its portfolio companies.

Formed in November 2021 by a joint venture between Lifepoint Health®, 25madison and Apollo Global Management (NYSE: APO), 25m Health is growing a portfolio of innovative startups that all target solutions aimed at improving access to high-quality care, enhancing the delivery of care across the healthcare continuum, and advancing value-based care.

By partnering with Clearwater, 25m Health is providing its portfolio companies with a cost-effective solution for building the cybersecurity and compliance capabilities needed to compete in the healthcare marketplace. Clearwater provides a deep team of experts and purpose-built software focused specifically on helping health tech companies make rapid progress in ensuring their organizations and technologies are market ready from a cybersecurity and compliance standpoint.

“Strong cybersecurity and compliance capabilities are a business imperative for any company developing technology for the healthcare industry,” said Ryan Macy, 25m Health’s Head of Engineering. “We’ve partnered with the industry leader in Clearwater to provide our companies with a very efficient solution that can easily scale as they grow within Lifepoint and beyond.

“With minimal disruption to founders and their teams, we’re proactively meeting the needs of healthcare providers who expect technologies being deployed within their organization to achieve the highest standards with respect to cybersecurity and compliance,” Macy added.

Key services being provided as part of the 25m Health-Clearwater partnership include:

• Establishing baseline target profiles for portfolio companies using the NIST Cybersecurity Framework and the 405(d) Health Industry Cybersecurity Practices
• vCISO support and advisory services
• Program governance
• Cloud security assessments
• Hardening guidance for the tech stack
• Portfolio monitoring and reporting

“Our partnership with 25m Health is another step forward in Clearwater’s initiative to help secure the next generation of healthcare technology innovators,” said Steve Cagle, Clearwater CEO. “We are deeply committed to advancing healthcare innovation by providing the industry’s strongest team of experts and tools focused on helping emerging technology companies build and mature the cybersecurity and compliance capabilities needed for success in our industry.”

About 25madison

25madison is a Venture Platform that incubates and invests in early-stage startups. 25madison consists of 25m Flagship, 25m Health, 25m Supply Chain, and 25m Evolve. 25madison also offers brand, marketing and UX design services through Creature, an agency that helps propel companies at pivotal moments. With a collaborative approach and a deep skillset across all business needs, 25madison partners with top entrepreneurs to turn high-conviction ideas into big businesses. Find out more at 25madison.com.

About Clearwater

Clearwater helps organizations across the healthcare ecosystem move to a more secure, compliant, and resilient state so they can achieve their mission. The company provides a deep pool of experts across a broad range of cybersecurity, privacy, and compliance domains, purpose-built software that enables efficient identification and management of cybersecurity and compliance risks, and a tech-enabled, 24x7x365 Security Operations Center with managed threat detection and response capabilities. To learn more, please visit www.clearwatersecurity.com.

For more information or press inquiries, please contact:

John Howlett
SVP and Chief Marketing Officer
Clearwater
john.howlett@clearwatersecurity.com
773.636.6449

New York, NY – Altaris, LLC (collectively with its affiliates, “Altaris”) is pleased to announce the appointment of Iain Baird as an Operating Partner. Mr. Baird has over 35 years of experience in the pharmaceutical industry, and will strengthen Altaris’ investment and operational activities in the sector. Mr. Baird has worked closely with Altaris for more than a decade, and he currently serves as a board director for Padagis and Kindeva.

Mr. Baird has a long track record of partnering with founders and management teams to build and optimize contract development and manufacturing organizations (CDMOs) and product companies across many therapeutic dosage formats, including: OSO BioPharmaceuticals, CANbridge Life Sciences, Gallus Biopharmaceuticals, Brammer Bio, Mikart, Arranta Bio, Vibalogics, Genezen, Enterobiotix and Meridian Medical Technologies.

Mr. Baird started his career at AstraZeneca (formerly ICI and Zeneca) where he designed and project managed the construction of pharmaceutical facilities and ran multiple production sites. Subsequently, Mr. Baird was a member of the leadership team that established Avecia Oligonucleotides as a contract manufacturing business and was also a founding team member of Avecia Vaccines, where he led the chemistry manufacturing and control groups in the development of vaccines against anthrax and plague. Mr. Baird received a Bachelor of Engineering in Mechanical and Electrical Engineering from Robert Gordons University.

Altaris is an investment firm exclusively focused on the healthcare industry. Altaris seeks to build market-leading companies that deliver innovation and efficiency to the healthcare system, with the ultimate goal of improving access and outcomes for patients. Altaris is headquartered in New York City and manages over $9.0 billion of equity capital. For more information, please visit www.altariscap.com.

New York, NY – Kindeva Drug Delivery (“Kindeva”), an operating company of Altaris, LLC (collectively with its affiliates, “Altaris”), announced today that it has acquired Summit Biosciences (“Summit”), an intranasal drug-delivery contract development and manufacturing organization, from its founding family shareholders.

Established in 2009, Summit has an extensive track record of innovation in the unit dose nasal spray market. The acquisition of Summit enhances Kindeva’s existing capabilities as a global leader in drug-device combination products by adding a new drug-delivery platform and expanding Kindeva’s ability to serve biopharma customers across a wider range of complex drug-device combination products (pulmonary, injectable, transdermal, and nasal).

Summit’s 55,000-square-foot cGMP facility in Lexington, Kentucky, adds to Kindeva’s global manufacturing footprint of nine development and manufacturing facilities across the U.S. and UK. The facility is approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and features specialized laboratories and integrated manufacturing operations with a long track record in bringing intranasal medicines to market.

Kirkland & Ellis acted as legal counsel to Kindeva. Frost Brown Todd acted as legal counsel, and Bourne Partners served as the exclusive financial advisor, to Summit.

About Altaris

Altaris is a healthcare investment firm with an exclusive focus on building companies that deliver value to the healthcare system through innovation and efficiency. Since inception in 2003, Altaris has invested in 50 healthcare companies which have generated significant value appreciation for investors. Altaris is headquartered in New York City and manages more than $9.0 billion of equity capital. For more information, please visit www.altariscap.com.

About Kindeva Drug Delivery

Kindeva is a global contract development manufacturing organization (CDMO) focused on drug-device combination products. The company develops and manufactures products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Kindeva’s service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our nine manufacturing, research, and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.

New York, NY – Altaris, LLC (collectively with its affiliates, “Altaris”) is pleased to announce the appointment of Brooks West as an Operating Partner. Mr. West brings a broad range of experience across the medical technology industry and will leverage his expertise to support Altaris’ investment and portfolio company development activities.

Mr. West has over 25 years of executive leadership, board and investment experience in medical technology industry. Previously, Mr. West was the President and CEO of BK Medical, an Altaris portfolio company and a global leader in intraoperative imaging. Mr. West joined BK Medical in 2017 and led its transformation and subsequent spinout from Analogic Corporation in 2018, culminating in the sale of the business to GE Healthcare for $1.45 Billion in 2021. Prior to BK Medical, Mr. West served for over a decade as a sell-side equity research analyst, most recently as a Senior Research Analyst covering medical technology at Piper Jaffray, in addition to a number of operating and investment banking roles. Mr. West received a Bachelor of Business Administration from Boston University.

Altaris is an investment firm exclusively focused on the healthcare industry. Altaris seeks to build market-leading companies that deliver innovation and efficiency to the healthcare system, with the ultimate goal of improving access and outcomes for patients. Altaris is headquartered in New York City and manages over $9.0 billion of equity capital. For more information, please visit www.altariscap.com.

WOODBURY, Minn. and St. LOUIS, Mo. and BOSTON; Dec. 5, 2023 – Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura^®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex^® 152a.

This strategic collaboration will focus on accelerating the conversion of existing marketed pMDI inhaler products to low global warming potential (GWP) pMDIs utilizing Koura’s Zephex 152a platform with the objective of reducing respiratory healthcare carbon emissions while safeguarding patient choice. This partnership aims to facilitate conversion of pMDI products to the lower GWP propellent 152a and progressing them through clinical development.

The converted pMDI products will be available for licensing with anticipated launches occurring in-line with the expected commencement of a phase-down of existing pMDI systems containing HFC-134a and HFC-227ea within the European Union.

Orbia Fluorinated Solutions Business (Koura) President Gregg Smith said, “This is a significant step forward in bringing our lower GWP medical propellant Zephex 152a to the market and we are excited to partner with Kindeva to ensure patients have access to this life saving technology.”

David Stevens, Global Chief Commercial Officer of Kindeva said, “We are proud to partner with Koura to help achieve the dual objectives of significantly reducing the environmental impact of pMDI inhalers and ensuring patient access to inhaler options is not compromised.”

Stevens continued, “Kindeva has a rich history of innovation in the pMDI market and our comprehensive development and manufacturing capabilities uniquely enable us to help lead this transition. This strategic collaboration is symbolic of not only the commitment both partners have for advancing sustainability and advocating for patient choice, but also of the shared values of the two organizations.”

Koura and Kindeva are both exhibiting at the Drug Delivery to the Lungs conference (DDL) in Edinburgh, U.K., December 6-8 (booth #146 and #147, respectively) where they will be speaking with industry leaders on the low GWP propellent, 152a, and further relevant topics.

About Kindeva Drug Delivery
Kindeva is a global contract development manufacturing organization focused on drug-device combination products. Kindeva develops and manufactures products across a broad range of complex drug-delivery formats, including injectables (autoinjector, intradermal, microneedle), pulmonary and nasal, and transdermal patches. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.

About Orbia
Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) is a company driven by a shared purpose: to advance life around the world. Orbia operates in the Polymer Solutions (Vestolit and Alphagary), Building and Infrastructure (Wavin), Precision Agriculture (Netafim), Connectivity Solutions (Dura-Line) and Fluorinated Solutions (Koura) sectors. The five Orbia businesses have a collective focus on expanding access to health and well-being, reinventing the future of cities and homes, ensuring food, water and sanitation security, connecting communities to information and enabling the energy transition with basic and advanced materials, specialty products and innovative solutions. Orbia has a global team of over 24,000 employees, commercial activities in more than 100 countries and operations in over 50, with global headquarters in Boston, Mexico City, Amsterdam and Tel Aviv. The company generated $9.6 billion in revenue and $1.95 billion of EBITDA in 2022. To learn more, visit: orbia.com.

About Orbia Fluorinated Solutions (Koura)
Orbia Fluorinated Solutions business, Koura, is a global leader in the development, manufacture and supply of fluoroproducts that play a fundamental role in enhancing everyday lives and shortening the path to a sustainable, circular economy. Backed by over 35 years of experience, Orbia Fluorinated Solutions (Koura) products are used in a vast range of applications including electric vehicles and energy storage, urban and rural infrastructure, indoor climate management, food and medicine refrigeration and even in treating respiratory conditions through the development of healthy and innovative low-GWP propellants for metered-dose inhalers. Orbia Fluorinated Solutions (Koura) has 1,600 employees and 13 manufacturing facilities worldwide, serving 60 countries through a global sales and distribution network.

 

Top Rankings in Black Book’s Survey of Nearly 3,800 Healthcare Executives
Reaffirms Breadth and Strength of Company’s Expertise and Capabilities

 

NASHVILLE, TN (November 29, 2023) – Clearwater, the largest pure-play provider of cybersecurity and compliance solutions for the healthcare industry, is proud to announce that it has been rated both the top Cybersecurity Advisors & Consultants and the top Compliance and Risk Management Solution in Black Book Market Research LLC’s annual “State of the Healthcare Cybersecurity Industry” report reviewing the industry’s best-performing cybersecurity software and services vendors. The latest recognition marks the fifth consecutive year that Clearwater has earned top ranking in both categories, and it follows the company’s rating as the top partner for Privacy, HIPAA and Compliance Services in another recent Black Book survey.

Black Book™ annually evaluates leading healthcare/medical software and service providers across 18 operational excellence key performance indicators (KPI) completely from the perspective of the client experience. Independent and unbiased from vendor influence, more than 1,300,000 healthcare IT users are invited to contribute to various annual customer satisfaction polls.

This year’s review of healthcare cybersecurity advisors and consultants received responses from nearly 3,800 healthcare executives representing nearly 1,900 different organizations across the ecosystem of hospitals and health systems, physician groups, health plans and insurers, and medical device manufacturers. In addition to its overall #1 ranking, Clearwater was the top-rated vendor in 13 of the 18 KPI categories reviewed by Black Book which range from client outcomes and improvements and advisor domain and body of knowledge to speed and efficiency of engagement deployment and return on investment.

More than 1,500 users of Compliance & Risk Management Solutions in healthcare provider and payer organizations participated in Black Book’s healthcare cybersecurity survey. Clearwater again led the way overall and also earned top honors in 12 of 18 KPI categories, including innovation & optimization, training, integration & interfaces, and support and customer care. The number one Compliance and Risk Management Solution rating for 2024 marks the eighth consecutive year that Clearwater has been recognized by Black Book as the leading vendor in that category.

Full rankings of hundreds of vendors can be viewed at https://blackbookmarketresearch.com/health-data-security-and-privacy.

“Delivering industry-leading value and exceeding client expectations is Clearwater’s number one priority,” said Clearwater CEO Steve Cagle. “I am very proud to see that the results of the latest Black Book survey once again validate the great work our team is doing to help our clients succeed. As we continue to grow the range of solutions we provide to the industry, we remain deeply committed to the mission of moving healthcare organizations to a more secure, compliant, and resilient state so they can achieve their mission.”

Clearwater’s comprehensive set of products and services includes:

Managed Services

Fully outsourced, expert-led, security, compliance, risk and privacy programs that create a force multiplier in protecting healthcare organizations.

Managed Security Services

24x7x365 monitoring, threat detection, vulnerability management, firewall management, and incident response that give clients an edge over threat actors.

Cybersecurity Services

A full range of expert security assessments, testing, remediation and execution services that drive tangible outcomes.

Privacy and Compliance Services

Rigorous yet efficient solutions that help clients achieve and maintain compliance with key regulations and standards, including HIPAA, HITRUST, and SOC 2.

IRM|Pro® Software

Award-winning software that provides insights and solutions to reduce risk and optimize security investments while enabling compliance.

Clearwater serves a diverse and growing base of clients across the healthcare industry, including some of the nation’s largest health systems as well as a large universe of regional hospitals, physician practice management groups, digital health and other healthcare technology companies, medical device manufacturers, and business service providers that share in the need to keep patients safe and protected health information secure while maintaining compliance with regulatory requirements.

 

About Clearwater

Clearwater helps organizations across the healthcare ecosystem move to a more secure, compliant, and resilient state so they can achieve their mission. The company provides a deep pool of experts across a broad range of cybersecurity, privacy, and compliance domains, purpose-built software that enables efficient identification and management of cybersecurity and compliance risks, and a tech-enabled, 24x7x365 Security Operations Center with managed threat detection and response capabilities. To learn more, please visit www.clearwatersecurity.com.

 

For more information or press inquiries, please contact:

John Howlett

SVP and Chief Marketing Officer

Clearwater

john.howlett@clearwatersecurity.com

773.636.6449

Intricon, developer and manufacturer of medical devices powered by smart miniaturized electronics, today announced that it has named Shaun Blakeman as its chief financial officer (CFO) and newest member of its executive team.

“Shaun is a seasoned global financial executive with 25+ years of operational and broad business experience as well as a proven record of results-driven impact,” said Scott Longval, Intricon chief executive officer. “I am confident we will benefit from Shaun’s leadership as we continue to transform the organization to drive enhanced growth, innovation, and value for our customers.”

Scott added that Shaun was selected given his deep understanding of the medical device industry and his expertise in finance for global businesses. He also has a proven track record in operations, logistics, engineering project management, and managing high-performing technical teams.

Most recently, Shaun was CFO at SomaLogic. He also served as CFO for Cantel Medical, now part of Steris, and in senior financial positions at Medtronic and IDEX Corporation. Shaun is a veteran of the U.S Navy, serving as an officer at sea and managing large technical projects. He earned an MBA from Indiana University’s Kelley School of Business, a master’s degree in applied physics from the Naval Postgraduate School, and an economics degree from the University of Minnesota.

“I am excited to join Intricon during this important period in the company’s transformation,” said Shaun. “Intricon is well-positioned to drive meaningful growth in its sensor-driven medical device business. I look forward to partnering closely with the leadership team and finance organization to enhance Intricon’s unique value proposition and execute its growth strategy.”

About Intricon

For four decades, Intricon has improved and extended people’s lives by developing and manufacturing sensor-driven micromedical devices. Intricon partners with medical device companies, providing unique microelectronic expertise — including miniature molding through final assembly – and regulatory guidance, supply chain optimization, and scalable production, exclusively for the medical market. Intricon brings the world’s smallest, smartest new and next-generation devices to life.